CLINICAL USE


Antibacterial agent

DOSE IN NORMAL RENAL FUNCTION

250–500 mg 4 times a dayAcne: 500 mg twice daily

PHARMACOKINETICS

  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :460.4
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :20–40
  • %Excreted unchanged in urine &nbsp &nbsp : 10–35

  • Volume of distribution (L/kg) &nbsp &nbsp &nbsp :1.5

  • half-life – normal/ESRD (hrs)&nbsp &nbsp &nbsp :9/66

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

  • 20 to 50 &nbsp &nbsp : Dose as in normal renal function
  • 10 to 20 &nbsp &nbsp : Dose as in normal renal function
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : 250 mg 4 times a day

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Not dialysed. Dose as in GFR <10 mL/min

  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Not dialysed. Dose as in GFR <10 mL/min
  • HDF/high flux &nbsp :Unknown dialysability. Dose as in GFR <10 mL/min
  • CAV/VVHD &nbsp &nbsp &nbsp:Unknown dialysability. Dose as in normal renal function

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugs
  • Anticoagulants: possibly enhanced anticoagulant effect of coumarins and phenindione
  • Oestrogens: possibly reduced contraceptive effects of oestrogens (risk probably small)
  • Retinoids: possible increased risk of benign intracranial hypertension with tetracyclines and retinoids – avoid concomitant use

    ADMINISTRATION

    Reconstition

    –

    Route

    Oral

    Rate of Administration

    –

    Comments

    –

    OTHER INFORMATION

    Avoid if possible in renal impairment, due to potential nephrotoxicity and increased risk of azotaemia, hyperphosphataemia and acidosisMay cause an increase in blood urea which is dose related. Avoid in SLE .
    Tags:

    • Related News

    sotalol hydrochloride.txt

    tazocin.txt